As of 2024-12-14, the Relative Valuation of Gensight Biologics SA (SIGHT.PA) is (1.98) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.32 EUR, the upside of Gensight Biologics SA based on Relative Valuation is -729.9%.
The range of the Relative Valuation is (1.72) - (1.34) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.2x - 13.5x | 9.8x |
| Forward P/E multiples | 4.0x - 4.8x | 4.4x |
| Fair Price | (1.72) - (1.34) | (1.98) |
| Upside | -644.6% - -526.1% | -729.9% |
| Date | P/E |
| 2024-12-13 | -1.13 |
| 2024-12-12 | -1.16 |
| 2024-12-11 | -1.12 |
| 2024-12-10 | -1.11 |
| 2024-12-09 | -1.14 |
| 2024-12-06 | -1.10 |
| 2024-12-05 | -1.12 |
| 2024-12-04 | -1.11 |
| 2024-12-03 | -1.13 |
| 2024-12-02 | -1.17 |
| 2024-11-29 | -1.33 |
| 2024-11-28 | -1.16 |
| 2024-11-27 | -1.18 |
| 2024-11-26 | -1.10 |
| 2024-11-25 | -1.11 |
| 2024-11-22 | -1.13 |
| 2024-11-21 | -1.14 |
| 2024-11-20 | -1.12 |
| 2024-11-19 | -1.15 |
| 2024-11-18 | -1.13 |
| 2024-11-15 | -1.18 |
| 2024-11-14 | -1.22 |
| 2024-11-13 | -1.22 |
| 2024-11-12 | -1.10 |
| 2024-11-11 | -1.11 |
| 2024-11-08 | -1.11 |
| 2024-11-07 | -1.13 |
| 2024-11-06 | -1.12 |
| 2024-11-05 | -1.14 |
| 2024-11-04 | -1.15 |
| 2024-11-01 | -1.10 |
| 2024-10-31 | -1.09 |
| 2024-10-30 | -1.14 |
| 2024-10-29 | -1.15 |
| 2024-10-28 | -1.18 |
| 2024-10-25 | -1.09 |
| 2024-10-24 | -1.01 |
| 2024-10-23 | -1.03 |
| 2024-10-22 | -1.13 |
| 2024-10-21 | -1.23 |
| 2024-10-18 | -1.24 |
| 2024-10-17 | -1.38 |
| 2024-10-16 | -1.44 |
| 2024-10-15 | -1.44 |
| 2024-10-14 | -1.51 |
| 2024-10-11 | -1.39 |
| 2024-10-10 | -1.33 |
| 2024-10-09 | -1.33 |
| 2024-10-08 | -1.36 |
| 2024-10-07 | -1.34 |